It has been shown to improve median overall survival in patients with metastatic HER2-positive breast cancer treated in the second-line setting compared to capecitabine plus lapatinib, with a hazard ratio of 0.68 (95% CI 0.55 to 0.85, p < 0.001) [64]. The gene discussed is ERBB2; the disease is breast carcinoma.